FrancophonIA/ELRC3.0 huggingface dataset:
English: White circular biconvex tablets, engraved ‘ESL 400'on one side and scored on the other side, with a diameter of 11 mm..
Croatian: Bijele okrugle bikonveksne tablete s utisnutim "ESL 400" na jednoj strani i urezom na drugoj strani, promjera 11 mm.
English: zebinix 200 mg (outer pack only)
Croatian: zebinix 200 mg (samo vanjsko pakiranje)
English: • Seizures;
Croatian: • Napadaji;
English: White oblong tablets, engraved ‘ESL 800'on one side and scored on the other side, with a length of 19 mm.
Croatian: Bijele duguljaste tablete s utisnutim "ESL 800" na jednoj strani i urezom na drugoj strani, dužine 19 mm.
English: In the newborn child
Croatian: Novorođenčad
English: Eslicarbazepine acetate was tested at doses of 1,200 mg and 1,600 mg once-daily.
Croatian: Eslikarbazepinacetat ispitivan je u dozama od 1200 mg i 1600 mg jednom dnevno.
English: zebinix 800 mg (outer pack only)
Croatian: zebinix 800 mg (samo vanjsko pakiranje)
English: In a study in healthy subjects, concomitant administration of eslicarbazepine acetate 1,200 mg once daily and phenytoin resulted in an average decrease of 31-33% in exposure to the active metabolite, eslicarbazepine, most likely caused by an induction of glucuronidation, and an average increase of 31-35% in exposure to phenytoin, most likely caused by an inhibition of CYP2C19.
Croatian: U ispitivanju u zdravih ispitanika, istodobna primjena eslikarbazepinacetata 1200 mg jednom dnevno i fenitoina rezultirala je u prosjeku padom od 31-33% u izloženosti aktivnom metabolitu eslikarbazepinu,
English: The tablets have ‘ESL 200'engraved on one side and are scored on the other side, with a length of 11 mm.
Croatian: Tablete imaju utisnuto "ESL 200" na jednoj strani i urez na drugoj strani, dužine su 11 mm.
English: Flavour Tutti-Frutti artificial (contains maltodextrin, propylene glycol, natural and artificial flavouring, and gum acacia (E414)
Croatian: saharinnatrij (E954), umjetna aroma tutti-frutti (sadrži maltodekstrin, propilenglikol, prirodne i umjetne arome i arapsku gumu (E414), maskirajuću aromu (sadrži propilenglikol, vodu i prirodne i umjetne arome) i pročišćena voda.
English: The tablets have ‘ESL 400'engraved on one side and are scored on the other side, with a diameter of 11 mm.
Croatian: Tablete imaju utisnuto "ESL 400" na jednoj strani i urez na drugoj strani, promjera su 11 mm.
English: zebinix 600 mg (outer pack only)
Croatian: zebinix 600 mg (samo vanjsko pakiranje)
English: • Sedation;
Croatian: • Sedacija;
English: Zebinix 200 mg tablets
Croatian: Zebinix 200 mg tablete
English: Zebinix 800 mg tablets
Croatian: Zebinix 800 mg tablete
English: Zebinix 800 mg tablets are white and oblong.
Croatian: Zebinix 800 mg tablete su bijele i duguljaste.
English: Zebinix 400 mg tablets
Croatian: Zebinix 400 mg tablete
English: Each tablet contains 200 mg of eslicarbazepine acetate.
Croatian: Jedna tableta sadrži 200 mg eslikarbazepinacetata.
English: Zebinix 600 mg tablets
Croatian: Zebinix 600 mg tablete
English: • if you have kidney problems.
Croatian: • imate problema sa bubrezima.
English: Severe cutaneous adverse reactions (SCARS) including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported in post-marketing experience with Zebinix treatment.
Croatian: severe cutaneous adverse reactions, SCARS) uključujući Stevens-Johnsonov sindrom (SJS) / toksičnu epidermalnu nekrolizu (TEN) i kožni osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl. drug reaction with eosinophilia and systemic symptoms, DRESS), koji mogu biti opasni po život ili imati smrtni ishod.
English: Eslicarbazepine acetate was tested at once-daily doses of 800 mg, 1,200 mg and 1,600 mg.
Croatian: Eslikarbazepinacetat ispitivan je u dozama od 800 mg, 1200 mg i 1600 mg primjenjivanim jednom dnevno.
English: Zebinix 800 mg tablets Eslicarbazepine acetate
Croatian: Zebinix 800 mg tablete eslikarbazepinacetat
English: Zebinix 200 mg tablets are white and oblong.
Croatian: Zebinix 200 mg tablete su bijele i duguljaste.
English: Each tablet contains 400 mg of eslicarbazepine acetate.
Croatian: Jedna tableta sadrži 400 mg eslikarbazepinacetata.
English: • Headache;
Croatian: • Padovi;
English: Each tablet contains 800 mg of eslicarbazepine acetate.
Croatian: Jedna tableta sadrži 800 mg eslikarbazepinacetata.
English: Contains methyl parahydroxybenzoate (E218) and sulphites See leaflet for further information
Croatian: Sadrži metilparahidroksibenzoat (E218) i sulfite.
English: • Medicine toxicity; • Anxiety.
Croatian: psihomotorna retardacija; anksioznost
English: Zebinix 200 mg tablets Eslicarbazepine acetate
Croatian: Zebinix 200 mg tablete eslikarbazepinacetat
English: • Diarrhoea;
Croatian: • Migrena;
English: Package leaflet: Information for the user Zebinix 200 mg tablets
Croatian: Uputa o lijeku: Informacije za korisnika Zebinix 200 mg tabletе eslikarbazepinacetat
English: Each tablet contains 600 mg of eslicarbazepine acetate.
Croatian: Jedna tableta sadrži 600 mg eslikarbazepinacetata.
English: Package leaflet: Information for the user Zebinix 800 mg tablets
Croatian: Uputa o lijeku: Informacije za korisnika Zebinix 800 mg tabletе eslikarbazepinacetat
English: Zebinix 600 mg tablets are white and oblong.
Croatian: Zebinix 600 mg tablete su bijele i duguljaste.
English: • Feeling generally weak, unwell or having chills;
Croatian: • Infekcija mokraćnih putova; • Osjećaj opće slabosti, loše osjećanje ili zimica;
English: Zebinix 400 mg tablets Eslicarbazepine acetate
Croatian: Zebinix 400 mg tablete eslikarbazepinacetat
English: • Bone metabolism disorder;
Croatian: Mijalgija, poremećaj metabolizma kostiju,
English: Zebinix 600 mg tablets Eslicarbazepine acetate
Croatian: Zebinix 600 mg tablete eslikarbazepinacetat
English: In the age group from 6 to 11 years of age, the most common adverse reactions observed in more than two patients treated with eslicarbazepine acetate were diplopia (9.5%), somnolence (7.4%), diziness (6.3%), convulsion (6.3%) and nausea (3.2%); in the age group from 12 to 18 years were somnolence (7.4%), vomiting (4.2%), diplopia (3.2%) and fatigue (3.2%).
Croatian: U dobnoj skupini od 6 do 11 godina najčešće nuspojave primijećene u više od dva bolesnika liječena eslikarbazepinacetatom bile su diplopija (9,5%), somnolencija (7,4%), omaglica (6,3%), konvulzije
English: Remove the bottle, the oral syringe and the bottle adapter from the box Step 2.
Croatian: 1. korak: Izvadite iz kutije bocu, štrcaljku za usta i nastavak
English: Package leaflet: Information for the user Zebinix 400 mg tablets
Croatian: Uputa o lijeku: Informacije za korisnika Zebinix 400 mg tabletе eslikarbazepinacetat
English: EU/1/09/514/007 30 tablets - ALU/ALU blister EU/1/09/514/008 60 tablets - ALU/ALU blister EU/1/09/514/009 30 tablets - PVC/ALU blister EU/1/09/514/010 60 tablets - PVC/ALU blister
Croatian: - Al/Al blister EU/1/09/514/009 30 tableta - PVC/Al blister EU/1/09/514/010 60 tableta - PVC/Al blister
English: Package leaflet: Information for the user Zebinix 600 mg tablets
Croatian: Uputa o lijeku: Informacije za korisnika Zebinix 600 mg tabletе eslikarbazepinacetat
English: • Itching;
Croatian: • Drhtavica;
English: The oral suspension is packaged in amber glass bottles with HDPE child resistant closures containing 200 ml oral suspension, inside a cardboard box.
Croatian: Oralna suspenzija je pakirana u bocama od smeđeg stakla s HDPE zatvaračem sigurnim za djecu i sadrže
English: Epistaxis, chest pain
Croatian: Epistaksa, bol u prsištu
English: (increase of ≥25%) compared to Baseline Parts III-V was 25.7%.
Croatian: (9,2 %) je liječeno ESL-om do kraja otvorenog dijela V.
English: • Shaking;
Croatian: • Proljev;
English: The National Competent Authorities of Member States or Reference Member States if applicable, shall ensure that the following condition is fulfilled by the MAH(s):
Croatian: Nacionalna nadležna tijela država članica ili referentnih država članica, ako je primjenljivo, osiguravaju da nositelj(i) odobrenja ispune sljedeći uvjet:
English: Suspension of the marketing authorisations should be lifted when bioequivalence to an EU Reference Medicinal Product has been established based on a bioequivalence study conducted visà-vis the EU Reference Medicinal Product.
Croatian: Privremeno oduzimanje odobrenja za stavljanje u promet lijeka treba se ukinuti nakon što je utvrđena bioekvivalencija s referentnim lijekom odobrenim unutar EU-a na temelju ispitivanja bioekvivalencije u odnosu na referentni lijek odobren unutar EU-a.
English: Conditions for lifting the suspension of the Marketing Authorisations
Croatian: Uvjeti za ukidanje privremenog oduzimanja odobrenja za stavljanje lijeka u promet
English: Annex III Condition for lifting the suspension of the Marketing Authorisations
Croatian: Uvjet za ukidanje privremenog oduzimanja odobrenja za stavljanje lijeka u promet
English: The recommended dose is 10 mg per kilogram bodyweight.
Croatian: Preporučena je doza 10 mg po kilogramu tjelesne težine.
English: The full EPAR for Zinplava can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Zinplava nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Zinplava bezlotoxumab
Croatian: Zinplava bezlotoksumab
English: It is given as a single infusion lasting around 1 hour.
Croatian: Lijek se daje jednokratnom infuzijom u trajanju od približno sat vremena.
English: What is Zinplava and what is it used for?
Croatian: Što je Zinplava i za što se koristi?
English: A new episode of diarrhoea was defined as 3 or more loose stools in 24 or fewer hours.
Croatian: Nova epizoda proljeva definirana je kao tri ili više mekanih stolica u 24 sata ili u kraćem razdoblju.
English: What measures are being taken to ensure the safe and effective use of Zinplava?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Zinplava?
English: This is a summary of the European public assessment report (EPAR) for Zinplava.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Zinplava.
English: The most common side effects with Zinplava (seen in more than 4 in 100 patients) are nausea (feeling sick), diarrhoea, fever and headache.
Croatian: Najčešće nuspojave lijeka Zinplava (zabilježene u više od 4 na 100 bolesnika) jesu mučnina, proljev, vrućica i glavobolja.
English: What are the risks associated with Zinplava?
Croatian: Koji su rizici povezani s lijekom Zinplava?
English: After an initial infection, some dormant forms of the bacteria (spores) may persist in the body and eventually produce further toxins, causing the symptoms to return.
Croatian: Nakon prvotne infekcije neki oblici bakterija u mirovanju (spore) mogu se zadržati u tijelu i s vremenom opet proizvoditi toksine te tako prouzročiti povratak simptoma.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Zinplava's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi lijeka Zinplava nadmašuju s njim povezane rizike te je preporučio davanje odobrenja za njegovu primjenu u Europskoj uniji.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zinplava have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Zinplava nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Why is Zinplava approved?
Croatian: Zašto je lijek Zinplava odobren?
English: It is not intended to provide practical advice on how to use Zinplava.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Zinplava.
English: Other information about Zinplava
Croatian: Ostale informacije o lijeku Zinplava
English: Zinplava has been shown to be effective at preventing recurrence of C. difficile infection, particularly in patients at high risk of the infection coming back (which occurs in about 15 to 35% of cases and is particularly difficult to treat).
Croatian: Lijek Zinplava pokazao se djelotvornim u sprječavanju recidiva infekcije bakterijom C. difficile, osobito u bolesnika izloženih visokom riziku povratka infekcije (koja se javlja u približno 15 do 35 % slučajeva i koja se osobito teško liječi).
English: Similar effects have been seen in patients on placebo.
Croatian: Slične su pojave zabilježene u bolesnika koji su primali placebo.
English: In the first study, 17% of patients given Zinplava (67 out of 386) had a new episode of diarrhoea in the 12 weeks after treatment compared with 28% of patients given placebo (109 out of 395).
Croatian: U prvom se ispitivanju u 17 % bolesnika koji su primali lijek Zinplava (u 67 od 386 bolesnika) pojavila nova epizoda proljeva unutar 12 tjedana nakon liječenja, u usporedbi s 28 % bolesnika koji su primali placebo (u 109 od 395 bolesnika).
English: For more information about treatment with Zinplava, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Zinplava pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: Zinplava is available as a concentrate to be made into a solution for infusion (drip) into a vein.
Croatian: Lijek Zinplava dostupan je kao koncentrat od kojeg se priprema otopina za infuziju (ukapavanje) u venu.
English: In the second study, figures were 16% (62 out of 395) for Zinplava and 26% (97 out of 378) for placebo.
Croatian: U drugom ispitivanju te su vrijednosti bile 16 % (u 62 od 395 bolesnika) u skupini koja je primala lijek Zinplava, u usporedbi s 26 % (u 97 od 378 bolesnika) u skupini koja je primala placebo.
English: What benefits of Zinplava have been shown in studies?
Croatian: Koje su koristi lijeka Zinplava dokazane u ispitivanjima?
English: antibody (a type of protein) that has been designed to attach to these toxins, blocking their action, thereby preventing further damage and diarrhoea from occurring.
Croatian: monoklonsko protutijelo (vrsta proteina) koje se veže za te toksine i sprječava njihovo djelovanje, a time i daljnja oštećenja te pojavu proljeva.
English: It is used to prevent future episodes of diarrhoea in patients who are taking antibiotics to treat their C. difficile infection and who are at high risk of the infection coming back.
Croatian: Primjenjuje se za sprječavanje budućih epizoda proljeva u bolesnika koji uzimaju antibiotike za liječenje infekcije uzrokovane bakterijom C. difficile i koji su izloženi visokom riziku povratka te infekcije.
English: Zinplava is a medicine used in adults who have infections due to bacteria called Clostridium difficile that cause severe diarrhoea.
Croatian: Zinplava je lijek koji se primjenjuje u odraslih osoba s infekcijama uzrokovanima bakterijom Clostridium difficile, koja uzrokuje jak proljev.
English: Bezlotoxumab is a monoclonal
Croatian: Bezlotoksumab je
English: C. difficile bacteria produce toxins that damage the lining of the gut causing diarrhoea which may be severe.
Croatian: Bakterija C. difficile proizvodi toksine koji oštećuju stijenku crijeva i uzrokuju proljev koji može biti jak.
English: For practical information about using Zinplava, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Zinplava bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: The effect was mainly seen in patients at higher risk of C. difficile infection coming back (such as older patients or those with a weakened immune system).
Croatian: Djelotvornost tog lijeka ponajprije je zabilježena u bolesnika koji su izloženi većem riziku povratka infekcije bakterijom C. difficile (na primjer u bolesnika starije dobi ili bolesnika oslabljenog imunosnog sustava).
English: How is Zinplava used?
Croatian: Kako se Zinplava koristi?
English: Zinplava is generally well tolerated with side effects similar to those observed in patients on placebo.
Croatian: Bolesnici općenito dobro podnose lijek Zinplava, a njegove su nuspojave slične nuspojavama zabilježenima u bolesnika koji su primali placebo.
English: How does Zinplava work?
Croatian: Kako djeluje Zinplava?
English: Zinplava given during antibiotic treatment was shown to be more effective than placebo (a dummy treatment) at preventing a new episode of diarrhoea caused by C. difficile infection in 2 main studies involving a total of 2,655 patients.
Croatian: U dvama glavnim ispitivanjima, u kojima je sudjelovalo ukupno 2 655 bolesnika, primjena lijeka Zinplava tijekom liječenja antibioticima pokazala se djelotvornijom od primjene placeba (slijepo liječenje) u sprječavanju nove epizode proljeva prouzročenog infekcijom bakterijom C. difficile.
English: For the full list of all side effects and restrictions with Zinplava, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Zinplava potražite u uputi o lijeku.
English: --1Live attenuated bovine respiratory syncytial virus (BRSV), strain Lym-56 104.7 - 6.5 CCID50* *Cell culture infectious dose 50%
Croatian: --1 Živi atenuirani goveđi respiratorni sincicijski virus (BRSV), soja Lym-56 . 104.7 - 6.5 CCID50* * Infektivna doza kulture stanica 50%
English: Route of administratio n
Croatian: Put primjene Unutarnjem pakovanju
English: Intravenous use vial (glass)
Croatian: Intravenska primjena bočica (staklena)
English: (Invented) name Strength Pharmaceutical Form Route of Administration
Croatian: Jačina Farmaceutski oblik
English: hours before taking the other.
Croatian: 3 sata prije uzimanja drugog.
English: After taking one of them, wait at least 2 to 3
Croatian: Poslije uzimanja jednog od njih pričekajte najmanje 2 do
English: When Comtess is given at higher doses:
Croatian: Kad je Comtess primijenjen u visokim dozama:
English: Other medicines and Comtess
Croatian: Drugi lijekovi i Comtess
English: Experience with Comtess in patients under 18 years is limited.
Croatian: Iskustvo s Comtessom u bolesnika mlađih od 18 godina je ograničeno.
English: • binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).
Croatian: • nekontrolirano prejedanje (jedenje velikih količina hrane u kratkom razdoblju) ili kompulzivno jedenje (jedenje više hrane nego što je normalno i potrebno za utaživanje gladi).
English: What Comtess is and what it is used for
Croatian: Što je Comtess i za što se koristi
English: Talk to your doctor or pharmacist before taking Comtess:
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete Comtess:
English: If you stop taking Comtess Do not stop taking Comtess unless your doctor tells you to.
Croatian: Ako prestanete uzimati Comtess Comtess nemojte prestati uzimati, osim ako Vam to ne kaže liječnik.
English: • altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive;
Croatian: • promijenjeno ili povećano zanimanje za spolnost i spolne odnose te ponašanje koje u značajnoj mjeri zabrinjava Vas ili druge, primjerice, pojačani seksualni nagon.
English: Date of first authorisation: 16 September 1998 Date of latest renewal: 3 September 2008
Croatian: Datum posljednje obnove: 3. rujna 2008.
English: • if you are taking certain antidepressants (ask your doctor or pharmacist whether your antidepressive medicine can be taken together with Comtess);
Croatian: • ako uzimate određene lijekove protiv depresije (upitajte svog liječnika ili ljekarnika može li se Vaš lijek protiv depresije uzimati zajedno s Comtessom);
English: What Comtess is and what it is used for What you need to know before you take Comtess How to take Comtess
Croatian: Što je Comtess i za što se koristi Što morate znati prije nego počnete uzimati Comtess Kako uzimati Comtess
English: There are large intra- and interindividual variations in the absorption of entacapone.
Croatian: Postoje velike intra- i interindividualne razlike u apsorpciji entakapona.
English: EU/1/98/082/001 30 film-coated tablets EU/1/98/082/002 60 film-coated tablets EU/1/98/082/003 100 film-coated tablets EU/1/98/082/005 175 film-coated tablets
Croatian: EU/1/98/082/001 30 filmom obloženih tableta EU/1/98/082/002 60 filmom obloženih tableta EU/1/98/082/003 100 filmom obloženih tableta EU/1/98/082/005 175 filmom obloženih tableta
English: What you need to know before you take Comtess
Croatian: Što morate znati prije nego počnete uzimati Comtess
English: Comtess may make it harder for you to digest iron.
Croatian: Comtess može otežati probavu željeza.
English: Therefore, the use of Comtess in children or adolescents cannot be recommended.
Croatian: Stoga se ne preporučuje primjena Comtessa u djece ili adolescenata.
English: yellow iron oxide (E 172), red iron oxide (E 172) and titanium dioxide (E 171).
Croatian: žuti željezov oksid (E 172), crveni željezov oksid (E 172) i titanijev dioksid (E 171).
English: Do not take Comtess
Croatian: Nemojte uzimati Comtess
English: If you forget to take Comtess
Croatian: Ako ste zaboravili uzeti Comtess
English: The safety and efficacy of Comtess in children below age 18 have not been established.
Croatian: Sigurnost i djelotvornost Comtessa u djece u dobi do 18 godina nisu ustanovljene.
English: If you experience such effects at the start of treatment with Comtess you should contact your doctor who may decide to adjust your dosage of levodopa.
Croatian: Ako osjetite te nuspojave na početku liječenja Comtessom, trebate se obratiti svom liječniku, koji može odlučiti o prilagođavanju doziranja levodope.
English: Comtess in association with levodopa may have a major influence on the ability to drive and use machines.
Croatian: Comtess udružen s levodopom može imati velik utjecaj na sposobnost upravljanja vozilima i strojevima.
English: Neuroleptic Malignant Syndrome (NMS) is a serious but rare reaction to certain medicines, and may occur especially when Comtess and other medicines to treat Parkinson's disease are suddenly stopped or the dose is suddenly reduced.
Croatian: Neuroleptički maligni sindrom (NMS) je ozbiljna ali rijetka reakcija na neke lijekove, i može se javiti naročito kada se naglo prekine uzimanje Comtessa i drugih lijekova za terapiju Parkinsonove bolesti, ili se njihova doza naglo smanji.
English: Comtess and iron supplements at the same time.
Croatian: Zbog toga ne uzimajte Comtess i preparate željeza u isto vrijeme.
English: Comtess has no effect on relieving the symptoms of Parkinson's disease unless taken with levodopa.
Croatian: Comtess nema učinak ublažavanja simptoma Parkinsonove bolesti ako nije uzet s levodopom.
English: Do not use Comtess during pregnancy or if you are breast-feeding.
Croatian: Comtess nemojte koristiti tijekom trudnoće i dojenja.
English: White high-density polyethylene (HDPE) bottles with white tamper proof polypropylene (PP) closures containing 30, 60, 100 or 175 tablets.
Croatian: Bijele polietilenske (HDPE) bočice visoke gustoće s bijelim sigurnosnim polipropilenskim (PP) zatvaračem koje sadrže 30, 60, 100 ili 175 tableta.
English: Comtess taken together with levodopa may lower your blood pressure, which may make you feel light-headed or dizzy.
Croatian: Comtess uzet zajedno s levodopom može sniziti Vaš krvni tlak, zbog čega možete osjetiti laganu ošamućenost ili omaglicu.
English: The maximum recommended dose is 10 tablets per day, i.e. 2,000 mg of Comtess.
Croatian: Najveća preporučena doza je 10 tableta na dan, odnosno 2000 mg Comtessa.
English: If you forget to take the Comtess tablet with your levodopa dose, you should continue the treatment by taking the next Comtess tablet with your next levodopa dose.
Croatian: Ako uz dozu levodope zaboravite uzeti Comtess, nastavite liječenje uzimanjem sljedeće Comtess tablete sa svojom sljedećom dozom levodope.